【1 月 17 日，招银国际发布研究报告称】巨子生物的可复美及可丽金在线 GMV 增长出色，集团上调去年业绩指引，预计收入增长超 50%，纯利升约 40%。招银国际继续看好公司护肤产线今年保持快速增长，并期待首款重组胶原蛋白注射类产品于今年首季获批。因巨子生物调升收入指引且优于预期，该行将集团 2023 至 25 财年的收入年复合增长率增至 43.5%，维持“买入”评级，将目标价由 66.15 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.